Factors Driving the Aspirin Exacerbated Respiratory Disease Phenotype

Steinke, John W.; Borish, Larry

doi:10.2500/ajra.2015.29.4123

Cited by 47 publications

(50 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AERD was originally defined by the “triad” of nasal polyps, asthma, and aspirin sensitivity (Samter’s triad) 33 . AERD tends to develop in adulthood and is recognized in as many as 30% of asthmatics with CRSwNPs 34 .…”

Section: Introductionmentioning

confidence: 99%

“…When present in patients who have avoided aspirin, pansinusitis on CT scan examination is suggestive of AERD 35 . NP in AERD is aggressive with multiple polyps that are characterized by rapid growth and – in the absence of medical management – universal recurrence after surgery 33 . These patients develop upper respiratory symptoms of nasal congestion, rhinorrhea, flushing, and paroxysmal sneezing, typically with exacerbations of their asthma after taking aspirin or other non-steroidal anti-inflammatory drugs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic rhinosinusitis phenotypes

Steinke

Borish

2016

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Chronic rhinosinusitis phenotypes

Steinke

Borish

2016

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

“…70,82,83 La desensibilización con aspirina está indicada en los pacientes que tienen falla con el tratamiento habitual, uso de esteroides orales, poliposis recurrente o que tienen alguna enfermedad de base, la cual requiera un antiinflamatorio no esteroideo. 84 La desensibilización a la aspirina mejora la poliposis nasosinusal, disminuye el número de episodios de infecciones, mejora los flujos pulmonares, disminuye el uso de esteroides orales y la necesidad de cirugía.…”

Section: 80unclassified

Guía Mexicana del Asma: GUIMA 2017

Larenas-Linnemann¹,

Salas-Hernández²,

Vázquez-García³

et al. 2017

RAM

View full text Add to dashboard Cite

Este artículo debe citarse como: Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, Del Río-Navarro BE, et al. Guía Mexicana del Asma 2017. Rev Alerg Mex. 2017;64 Supl 1:s11-s128. AbstractBackground: The need for a national guideline, with a broad basis among specialists and primary care physicians was felt in Mexico, to try unifying asthma management. As several high-quality asthma guidelines exist worldwide, it was decided to select the best three for transculturation. Methods: Following the internationally recommended methodology for guideline transculturation, ADAPTE, a literature search for asthma guidelines, published 1-1-2007 through 31-12-2015 was conducted. AGREE-II evaluations yielded 3/40 most suitable for transculturation. Their compound evidence was fused with local reality, patient preference, cost and safety considerations to draft the guideline document. Subsequently, this was adjusted by physicians from 12 national medical societies in several rounds of a Delphi process and 3 face-to-face meetings to reach the final version. Results: Evidence was fused from British Thoracic Society Asthma Guideline 2014, Global Initiative on Asthma 2015, and Guía Española del Manejo del Asma 2015 (2016 updates included). After 3 Delphi-rounds we developed an evidence-based document taking into account patient characteristics, including age, treatment costs and safety and best locally available medication. Conclusion: In cooperation pulmonologists, allergists, ENT physicians, paediatricians and GPs were able to develop an evidence-based document for the prevention, diagnosis and treatment of asthma and its exacerbations in Mexico.Keywords: Clinical practice guideline; Asthma; Asthmatic exacerbation; Bronchodilator; Inhaled corticosteroid; Spirometry; Immunotherapy. IntroducciónLa presentación de este documento muestra la importancia del asma en México por su alta prevalencia, pero también por su subdiagnóstico y tratamiento deficiente, que propician un mal control de los pacientes con asma, crisis más frecuentes y sintomatología activa. En consecuencia, el asma tiene un impacto socioeconómico considerable para el paciente y la sociedad en su conjunto, al igual que afecta la calidad de vida del paciente y su familia. En México, el paciente con asma puede recibir atención médica en los ámbitos pú-blico o privado, en los diferentes niveles de salud y por múltiples especialidades. Todas estas particularidades de la situación nacional indican la necesidad de un documento guía actualizado, con base amplia en múltiples gremios médicos, tanto de primer nivel de atención como de especialidad.El objetivo de la GUIMA 2017 es facilitar la reducción de la morbimortalidad por asma en México, no solo al mejorar el conocimiento acerca de esta patología, sino también al ayudar a la parte administrativa del Sector Salud a gestionar la selección y adquisición más precisa de los medicamentos necesarios para su tratamiento a nivel de la salud pública. Para tal fin se ofrecen lineamientos par...

show abstract

“…As with idiopathic eosinophilic asthma this is a phenotype most often presenting in adulthood and atopy is not an essential component. The defining features include the presence of severe chronic rhinosinusitis with nasal polyps and the sensitivity to aspirin and other non-selective inhibitors of cyclooxygenase 13 .…”

Section: Introductionmentioning

confidence: 99%